The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24‐Week, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study with a 28‐Week Extension
Abstract
Objectives: To assess the efficacy of dapagliflozin, a sodium–glucose cotransporter 2 inhibitor, for the treatment of individuals with type 2 diabetes mellitus (T2 DM ) and preexisting cardiovascular disease ( CVD ). Design: Randomized, double‐blind, age‐stratified (<65 and ≥65), 24‐week clinical trial with a 28‐week extension. Setting: One hundred seventy‐three centers in 10 countries. Participants: Individuals (N = 964) with T2 DM , glycosylated hemoglobin (HbA1c) of 7.0% to 10.0%, and documented CVD . Intervention: Dapagliflozin 10 mg/d or placebo was added to usual care. Participants receiving insulin had their total daily insulin dose reduced by 25% at randomization. Measurements: Two equal primary end points: change from baseline in HbA1c and proportion of participants achieving a three‐item end point (reduction of ≥0.5% in HbA1c, ≥3% in body weight, and ≥3 mmHg in systolic blood pressure) at 24 weeks. Results: Forty‐seven percent were aged 65 and older, 7.7% were aged 75 and older, mean duration of T2 DM was 13 years, mean baseline HbA1c was 8.1%, and approximately 60% were taking insulin. The placebo‐corrected change in HbA1c with dapagliflozin was −0.4% at 24 weeks. Significantly more participants achieved the three‐item end point with dapagliflozin (10.0%) than with placebo (1.9%). The placebo‐corrected percentage change in body weight for dapagliflozin was −1.9% (−1.8 kg). Similar results were observed in both age strata, and changes were maintained over 52 weeks. More than one‐quarter (28.2%) of participants receiving dapagliflozin and 25.3% of those receiving placebo experienced hypoglycemia. More participants receiving dapagliflozin had vulvovaginitis, balanitis, or urinary tract infection. Conclusion: When added to a usual background regimen in an older population with advanced T2 DM and preexisting comorbid CVD , dapagliflozin improved glycemic control without an increase in hypoglycemic risk, promoted weight loss, and was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Kirkman, M. S., Briscoe, V. J., Clark, N., Florez, H., Haas, L. B., Halter, J. B., Huang, E. S., Korytkowski, M. T., Munshi, M. N., Odegard, P. S., et al. (2012) · Diabetes Care · doi:10.2337/dc12-1801 · Cited by 1,274
Long-term effects of intensive glucose lowering on cardiovascular outcomes
The ACCORD Study Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1006524 · Cited by 1,035
Bolinder, J., Ljunggren, Ö., Kullberg, J., Johansson, L., Wilding, J., Langkilde, A. M., Sugg, J., & Parikh, S. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2260 · Cited by 867
Self-citationSodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698
Sinclair, A., Morley, J. E., Rodriguez-Mañas, L., Paolisso, G., Bayer, T., Zeyfang, A., Bourdel-Marchasson, I., Vischer, U., Woo, J., Chapman, I., et al. (2012) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2012.04.012 · Cited by 422
Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., & Pfister, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.250 · Cited by 396
Cited by
Scheen, A. J. (2015) · Drugs · doi:10.1007/s40265-014-0337-y · Cited by 554
Zaccardi, F., Webb, D. R., Htike, Z. Z., Youssef, D., Khunti, K., & Davies, M. J. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12670 · Cited by 489
Wu, J. H. Y., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundström, J., & Neal, B. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00052-8 · Cited by 474
Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences
Gallo, L. A., Wright, E. M., & Vallon, V. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114561992 · Cited by 395
Mazidi, M., Rezaie, P., Gao, H., & Kengne, A. P. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004007 · Cited by 347
Metadata
- Authors
- Leiter, L. A., Cefalu, W. T., de Bruin, T. W. A., Gause‐Nilsson, I., Sugg, J., & Parikh, S. J.
- Venue
- Journal of the American Geriatrics Society
- Publisher
- Wiley
- Published
- 2014-06-02
- Volume
- 62
- Issue
- 7
- Pages
- 1252-1262
- ISSN
- 0002-8614 (ISSN-L)
- 1532-5415
- OpenAlex
- W2054361323
- Cited by
- 182
- References
- 8
- FWCI
- 14.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24‐Week, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study with a 28‐Week Extension. https://app.cochat.ai/papers/10.1111/jgs.12881
- The paper
- Leiter, L. A., Cefalu, W. T., de Bruin, T. W. A., Gause‐Nilsson, I., Sugg, J., & Parikh, S. J. (2014). Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24‐Week, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study with a 28‐Week Extension. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.12881
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.